Dactolisib

Research use only, not for human use.

A potent, dual ATP-competitive pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM, respectively.

A potent, dual ATP-competitive pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM, respectively; effectively and specifically blocks the dysfunctional activation of the PI3K pathway, inducing G(1) arrest; demonstrates antitumor activity in in vivo models of human cancer.Kidney Cancer Phase 2 Discontinued

NVP-BEZ235;BEZ-235

PI3K/Akt/mTOR signaling

PI3K

ATR;mTOR(p70S6K);p110α;p110γ;p110δ;p110β

Cancer

Kidney Cancer

915019-65-7

469.54

C30H23N5O

>98% (HPLC)

DMSO: 8.75 mg/mL

CC(C1=CC=C(N(C2=C3C=NC4=CC=C(C5=CC6=CC=CC=C6N=C5)C=C24)C(N3C)=O)C=C1)(C)C#N

Benzeneacetonitrile, 4-[2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4,5-c]quinolin-1-yl]-.alpha.,.alpha.-dimethyl-

(-20℃)

With Ice Pack

≥ 2 years